respiratory
Cystic fibrosis

OPTIMIZE trial: long term azithromycin preserves lung function in CF children


The longest randomised controlled trial of azithromycin treatment in children with cystic fibrosis has shown a 44% reduction in exacerbations over 18 months. The OPTIMIZE trial conducted in 221 US children with CF aged 6 months-18 years with recent Pseudomanas aeruginosa acquisition also found that regular treatment with oral azithromycin appears safe when the macrolide ...

Already a member?

Enter your email to keep reading.


OR